<DOC>
	<DOCNO>NCT01657370</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics MK-1602 treatment acute migraine , include influence demographic variable MK-1602 pharmacokinetics , evaluate relationship MK-1602 concentration efficacy drug .</brief_summary>
	<brief_title>A Pharmacokinetic Study MK-1602 Treatment Acute Migraine ( MK-1602-007 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>&gt; 1 year history migraine without aura define International Headache Society ( IHS ) criteria 1.1 and/or 1.2 Migraines typically last 4 72 hour , untreated ≥ 2 ≤ 8 moderate severe migraine attack per month two month prior screen Male , female reproductive potential , female reproductive potential screening serum βhuman chorionic gonadotropin ( βhCG ) level consistent notpregnant state , agree use acceptable contraception Pregnant breastfeeding , female expect conceive within project duration study participation Participant difficulty distinguish his/her migraine attack tensiontype headache History predominantly mild migraine attack migraine usually resolve spontaneously less two hour More 15 headachedays per month take medication acute headache 10 day per month three month prior screen Basilartype hemiplegic migraine headache &gt; 50 year old age migraine onset Taking migraine prophylactic medication prescribe daily dose change 3 month prior screen study Taking proton pump inhibitor ( PPI ) histamine receptor 2 ( H2 ) blocker daily near daily basis ( &gt; 3 day per week ) Taking follow medication 1 month prior screen study period : potent cytochrome P450 ( CYP ) 3A4 inhibitor ( e.g. , cyclosporine , itraconazole , ketoconazole , fluconazole , erythromycin , clarithromycin , nefazodone , telithromycin , cimetidine , quinine , diltiazem , verapamil , modafinil human immunodeficiency virus [ HIV ] protease inhibitor ) , moderate mark CYP3A4 inducer ( e.g. , rifampicin , rifabutin , barbiturates [ e.g. , phenobarbital primidone ] , systemic glucocorticoid , nevirapine , efavirenz , pioglitazone , carbamazepine , phenytoin , St. Johns wort ) , drug narrow therapeutic margin potential drug interaction CYP2C family ( e.g. , warfarin ) Participant unable refrain consumption grapefruit grapefruit juice study History hypersensitivity , experience serious adverse event response 3 class drug ( prescription overthecounter ) Clinical laboratory evidence uncontrolled diabetes , HIV disease , significant pulmonary , renal , hepatic , endocrine , systemic disease Other confound pain syndrome , psychiatric condition uncontrolled major depression , dementia significant neurological disorder migraine . Patients currently treat nonprohibited medication depression symptom well control eligible participate Participant imminent risk selfharm History malignancy ≤ 5 year prior study , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer History gastric small intestinal surgery ( include gastric bypass surgery banding ) , presence disease cause malabsorption History current evidence condition , therapy , lab abnormality circumstance might confound result study , interfere subject 's participation full duration study Participant recent history ( within last year ) drug alcohol abuse dependence user recreational illicit drug Participant legally mentally incapacitated Donation blood product phlebotomy &gt; 300 ml within 8 week study , intent donate blood product receive blood product within 30 day screen throughout study Intent donate egg sperm within project duration study Current participation participation within 30 day screen study investigational compound device , exception MK1602 Protocol 006 Previous exposure MK0974 and/or MK3207 Use within past 2 month opioid barbituratecontaining analgesic migraine relief Inpatient emergency department treatment acute migraine attack within past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>